Editas Medicine Falls as Goldman Sachs Initiates the Stock at Sell

 Editas Medicine  (EDIT) - Get Report dropped Friday after analysts at Goldman Sachs initiated coverage on shares off the company with a sell rating and a price target of $20 a share, a Wall Street low. 

The firm said the risk-reward dynamic was skewed negatively for the clinical stage genome editing company. 

Initial results from the company's experimental Crispr gene editing product EDIT-11 in a rare eye disease may not generate enough productive editing to meaningfully improve patients' vision, analyst Madhu Kumar said in his note initiating coverage on the stock.

https://www.thestreet.com/investing/editas-medicine-edit-goldman-sell-initiation